GALT

Galectin Therapeutics Inc. (GALT) | Rumor.io

Galectin Therapeutics

GALT

Attention (50-day avg)0.01%

Attention rank (50-day avg)#637

Bullish sentiment (50-day avg)80%

Price to earnings ratio-8.17

Market capitalization396.3M

Earnings per share-0.43

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-30.8M

Social

What share of all stock conversation is about GALT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% 0	0.01% 0	0.01% -0.01

Sep 29

The company is waiting for a Phase 3 protocol filing announcement, which may be accompanied by a partnership or buyout.
The stock has been accumulating in dark pools, with 66% of shares being held in dark pools on one day, indicating a potential increase in buying activity.
The company's low volume and light trading may be a sign that institutions are having trouble finding shares to short, which could lead to a short squeeze.

Generated by AI

Sentiment

Of the messages about GALT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	75% -25	74.22% -19.05	81.57% +0.65	80.66% +12.7
Bearish	25% new	25.78% +19.05	18.43% -0.65	19.34% -12.7

Bullish· Sep 15

Galectin Therapeutics Inc. (GALT) has shown impressive results in clinical trials, including preventing varices in completers with a clear clinical outcome backed by positive data points.
The company's antifibrotic MOA is a unique and leading approach in the industry, with a strong presence in key conferences and partnerships with key opinion leaders (KOLs).
Despite market volatility, long-term investors are accumulating shares, with some expecting a potential buyout with a CVR (contingent value rights) and significant interest from big pharma.

Bearish· Sep 15

The CEO's performance at the conference was unacceptable, and he seemed either afraid to speak or incapable of discussing the company in any depth.
The company's management team is being criticized for their inexperience and inability to land a deal, with some calling for a change at the top.
The stock price has tanked, and investors are unhappy with the company's performance, with some even suggesting that the CEO should sell the company to spite them.

Generated by AI

Topics

Of the messages about GALT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	75%	54.68%
Announcements	—	100%	25%	36.42%
Analysts	—	0%	0%	3.35%
Controversies	—	0%	0%	1.39%
Earnings	—	0%	0%	0.12%
Macro	—	0%	0%	4.03%

Analysts· Mar 30

Galectin Therapeutics Inc. ($GALT) has been upgraded to Buy by H.C. Wainwright, with a price target of $3.50, representing a 77% upside.
Analyst Ed Arce at H.C. Wainwright has increased his confidence in a positive data readout for Galectin Therapeutics in December, citing NASH-CX results as a major stock catalyst.
H.C. Wainwright has raised its price target for Galectin Therapeutics to $3.50, upgrading the stock from Neutral to Buy.

Announcements· Oct 12

Galectin Therapeutics Inc. ($GALT) received FDA approval to proceed with a combination immunotherapy trial in head and neck cancer.
The company has also received a Study May Proceed letter for a Phase 2 clinical trial and will continue to focus on its pivotal global NAVIGATE trial in NASH cirrhosis.
Enrollment for the NAVIGATE trial is expected to be completed by the end of 2022.

Technical Analysis· Jul 9

$GALT's short percentage is 20, with relative volume over 360x normal, indicating potential afternoon action.
The chart is bullish, having broken above the 50 SMA on high volume, with next levels to take out being $4 and $4.45 for a potential move to $5.
$GALT needs to break descending resistance and get above $4.10 to break the VWAP, with support on the 200 on the 1-minute chart.

Generated by AI

Community

Of the messages about GALT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	96.78%	97.94%	92.65%
Newcomers	0%	3.22%	2.06%	7.35%

Regulars· Sep 29

The regulars are anticipating a potential partnership or buyout (BO) announcement, possibly in conjunction with a Phase 3 protocol filing.
The dark pool activity has increased, with 66% of trading volume being unreported, indicating that shares may be difficult to find for short sellers.
There is speculation about potential surprises in the Phase 3 protocol filing, including international clinical trial sites, expanded trial design, or timeline slippage.

Newcomers· Dec 19

Galectin Therapeutics Inc.'s stock price has decreased due to FDA feedback on its drug, belapectin, and its clinical trial design.
The company has secured a $10 million credit line to cover upcoming expenditures despite the challenges with the FDA.
Insider sales of GALT stock have been significant, with 82,451 shares sold at an average price of $6.90, resulting in a total value of $568,872.53.

Generated by AI

Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences (NASDAQ:JUNS) stock

14d agoBenzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session

14d agobenzinga.com

Galectin Therapeutics at H.C. Wainwright: belapectin nears phase III

15d agoInvesting.com

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

NORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present and attend the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY. Presentation details:Format: Company presentation and 1 on 1 meetingsDate & time: September 14th, 2026, at 11:30 AM ETWebcast: https://journey.ct.events/view/c

20d agoYahoo Finance

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026. “We had a very productive second quarter. Importantly, we reached an agreement with the FDA on the key elements of our planned Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension and aligned on the regulatory path

1mo agoYahoo Finance Singapore

Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion

Detailed price information for Galectin Therapeutic (GALT-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about GALT also mention

#	Name	Attention
1	ICPT - Intercept Pharmaceuticals, Inc.	——
2	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
3	GNFT - Genfit S.A.	——
4	Eocene Ltd.GLMD	0%0
5	Utstarcom Holdings Corp.UTSI	0%new
6	Geron CorporationGERN	0%0
7	CBAY - CymaBay Therapeutics, Inc.	——
8	MRNS - Marinus Pharmaceuticals, Inc.	——
9	BLPH - Bellerophon Therapeutics, Inc.	——
10	Research Frontiers IncorporatedREFR	0%0

Galectin Therapeutics Inc.

Healthcare
Biotechnology

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease, cancer, and selected other chronic conditions. Galectin Therapeutics uses a carbohydrate-based approach centered on galectin science, targeting galectin proteins that play key roles in inflammation, fibrosis, and malignancy. Its lead product candidate, belapectin, is a galectin-3 inhibitor being studied in programs related to metabolic dysfunction-associated steatohepatitis, liver fibrosis, cirrhosis, and portal hypertension. The company also supports research into additional galectin-related treatments, including oral small-molecule inhibitors through collaborative efforts. Galectin Therapeutics is based in Norcross, Georgia, and operates within the biotechnology sector, where it focuses on discovery and development rather than commercial-scale product sales.

Website

Location

4960 Peachtree Industrial Boulevard

Norcross, GA, 30071

United States

Social

What share of all stock conversation is about GALT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% 0	0.01% 0	0.01% -0.01

Sep 29

The company is waiting for a Phase 3 protocol filing announcement, which may be accompanied by a partnership or buyout.
The stock has been accumulating in dark pools, with 66% of shares being held in dark pools on one day, indicating a potential increase in buying activity.
The company's low volume and light trading may be a sign that institutions are having trouble finding shares to short, which could lead to a short squeeze.

Generated by AI

Sentiment

Of the messages about GALT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	75% -25	74.22% -19.05	81.57% +0.65	80.66% +12.7
Bearish	25% new	25.78% +19.05	18.43% -0.65	19.34% -12.7

Bullish· Sep 15

Galectin Therapeutics Inc. (GALT) has shown impressive results in clinical trials, including preventing varices in completers with a clear clinical outcome backed by positive data points.
The company's antifibrotic MOA is a unique and leading approach in the industry, with a strong presence in key conferences and partnerships with key opinion leaders (KOLs).
Despite market volatility, long-term investors are accumulating shares, with some expecting a potential buyout with a CVR (contingent value rights) and significant interest from big pharma.

Bearish· Sep 15

The CEO's performance at the conference was unacceptable, and he seemed either afraid to speak or incapable of discussing the company in any depth.
The company's management team is being criticized for their inexperience and inability to land a deal, with some calling for a change at the top.
The stock price has tanked, and investors are unhappy with the company's performance, with some even suggesting that the CEO should sell the company to spite them.

Generated by AI

Topics

Of the messages about GALT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	75%	54.68%
Announcements	—	100%	25%	36.42%
Analysts	—	0%	0%	3.35%
Controversies	—	0%	0%	1.39%
Earnings	—	0%	0%	0.12%
Macro	—	0%	0%	4.03%

Analysts· Mar 30

Galectin Therapeutics Inc. ($GALT) has been upgraded to Buy by H.C. Wainwright, with a price target of $3.50, representing a 77% upside.
Analyst Ed Arce at H.C. Wainwright has increased his confidence in a positive data readout for Galectin Therapeutics in December, citing NASH-CX results as a major stock catalyst.
H.C. Wainwright has raised its price target for Galectin Therapeutics to $3.50, upgrading the stock from Neutral to Buy.

Announcements· Oct 12

Galectin Therapeutics Inc. ($GALT) received FDA approval to proceed with a combination immunotherapy trial in head and neck cancer.
The company has also received a Study May Proceed letter for a Phase 2 clinical trial and will continue to focus on its pivotal global NAVIGATE trial in NASH cirrhosis.
Enrollment for the NAVIGATE trial is expected to be completed by the end of 2022.

Technical Analysis· Jul 9

$GALT's short percentage is 20, with relative volume over 360x normal, indicating potential afternoon action.
The chart is bullish, having broken above the 50 SMA on high volume, with next levels to take out being $4 and $4.45 for a potential move to $5.
$GALT needs to break descending resistance and get above $4.10 to break the VWAP, with support on the 200 on the 1-minute chart.

Generated by AI

Community

Of the messages about GALT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	96.78%	97.94%	92.65%
Newcomers	0%	3.22%	2.06%	7.35%

Regulars· Sep 29

The regulars are anticipating a potential partnership or buyout (BO) announcement, possibly in conjunction with a Phase 3 protocol filing.
The dark pool activity has increased, with 66% of trading volume being unreported, indicating that shares may be difficult to find for short sellers.
There is speculation about potential surprises in the Phase 3 protocol filing, including international clinical trial sites, expanded trial design, or timeline slippage.

Newcomers· Dec 19

Galectin Therapeutics Inc.'s stock price has decreased due to FDA feedback on its drug, belapectin, and its clinical trial design.
The company has secured a $10 million credit line to cover upcoming expenditures despite the challenges with the FDA.
Insider sales of GALT stock have been significant, with 82,451 shares sold at an average price of $6.90, resulting in a total value of $568,872.53.

Generated by AI

Galectin Therapeutics

Social

Sep 29

Bullish· Sep 15

Bearish· Sep 15

Analysts· Mar 30

Announcements· Oct 12

Technical Analysis· Jul 9

Regulars· Sep 29

Newcomers· Dec 19

12 Health Care Stocks Moving In Tuesday's After-Market Session - Tempest Therapeutics (NASDAQ:TPST), Jupi

12 Health Care Stocks Moving In Tuesday's After-Market Session

Galectin Therapeutics at H.C. Wainwright: belapectin nears phase III

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion

Also Discussed

Galectin Therapeutics Inc.

Company Information

Location

12 Health Care Stocks Moving In Tuesday's After-Market Session - Tempest Therapeutics (NASDAQ:TPST), Jupi

12 Health Care Stocks Moving In Tuesday's After-Market Session

Galectin Therapeutics at H.C. Wainwright: belapectin nears phase III

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion

Also Discussed

Social

Sep 29

Bullish· Sep 15

Bearish· Sep 15

Analysts· Mar 30

Announcements· Oct 12

Technical Analysis· Jul 9

Regulars· Sep 29

Newcomers· Dec 19